eClinical Technology and Industy News

ORYZON Announces First Patient In in NET, a Collaborative Phase II Basket Study With Iadademstat in R/R Patients With Neuroendocrine Carcinomas

  • Collaborative study with Fox Chase Cancer Center
  • Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs
  • Part of a broad collaboration with The Cancer Epigenetics Institute (CEI)

Excerpt from the Press Release:

MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC). This trial is conducted under a collaborative clinical research agreement entered between Oryzon and the Fox Chase Cancer Center (FCCC), under which FCCC will be conducting different collaborative combination clinical trials with iadademstat, with Oryzon providing funding, the drug and technical expertise.

NET (NCT05420636) is an open-label basket study conducted by FCCC as the sponsor, with Dr. Namrata Vijayvergia, MD, Assistant Chief, Gastrointestinal Medical Oncology, member of the Cancer Epigenetics Institute, and Nuclear Dynamics and Cancer program at Fox Chase Cancer Center, as the principal investigator. The trial will assess the safety and efficacy of iadademstat in combination with paclitaxel in patients with relapsed/refractory small cell lung cancer or extrapulmonary high grade NECs.

Neuroendocrine neoplasms are rare and heterogeneous cancers arising from neuroendocrine cells, representing 0.5% of all newly diagnosed malignancies, with a prevalence of 100,000 cases in the US. 22-27% of NETs are pulmonary (i.e., small cell lung cancer, SCLC), and the remainder are extrapulmonary, with gastrointestinal tract as the most common presentation followed by genito-urinary tumors.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?